Table 1 Demographic and baseline subject characteristics
Placebo | GSK2190915 10 mg QD | GSK2190915 30 mg QD | GSK2190915 100 mg QD | GSK2190915 300 mg QD | FP 100 μg BID | Montelukast 10 mg QD | |
|---|---|---|---|---|---|---|---|
N = 100 | N = 99 | N = 100 | N = 100 | N = 101 | N = 103 | N = 97 | |
n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
Age in years; Mean [range] | 42.3 [12–71] | 40.0 [12–75] | 43.1 [12–73] | 42.2 [12–69] | 42.2 [12–69] | 41.5 [12–74] | 44.3 [15–78] |
BMI in kg/m2; Mean [range] | 27.5 [16–47] | 27.5 [17–49] | 26.8 [16–43] | 27.8 [16–52] | 26.9 [19–63] | 27.0 [15–55] | 27.1 [18–54] |
Sex; n (%) | |||||||
Female | 88 (88) | 91 (92) | 94 (94) | 92 (92) | 93 (92) | 97 (94) | 89 (92) |
Male | 12 (12) | 8 (8) | 6 (6) | 8 (8) | 8 (8) | 6 (6) | 8 (8) |
Race; n (%) | |||||||
White | 82 (82) | 74 (75) | 78 (78) | 78 (78) | 78 (77) | 83 (81) | 76 (78) |
Black | 6 (6) | 12 (12) | 10 (10) | 9 (9) | 9 (9) | 7 (7) | 9 (9) |
Other | 12 (12) | 13 (13) | 12 (12) | 13 (13) | 14 (14) | 13 (13) | 12 (12) |
Smoking-history; n (%) | |||||||
Never smoked | 78 (78) | 85 (86) | 83 (83) | 77 (77) | 86 (85) | 86 (83) | 78 (80) |
Current smoker | 12 (12) | 9 (9) | 10 (10) | 11 (11) | 10 (10) | 13 (13) | 13 (13) |
Former smoker | 10 (10) | 5 (5) | 7 (7) | 12 (12) | 5 (5) | 4 (4) | 6 (6) |
FEV1 in L; Mean [range] | 2.0 [1.2–3.7] | 2.0 [1.0–3.3] | 1.9 [1.1–2.8] | 2.0 [1.0–3.5] | 2.0 [1.1–3.4] | 2.0 [1.0–4.0] | 2.0 [0.9–3.5] |
% predicted; Mean [range] | 68.7 [51–87] | 67.7 [50–96] | 66.1 [50–85] | 67.8 [51–85] | 66.8 [51–85] | 66.6 [37–85] | 69.2 [50–85] |
Atopy, n% | 22 (22) | 30 (30) | 31 (31) | 31 (31) | 35 (35) | 35 (34) | 34 (35) |